Browse
Submit Data
Databases
API
Help

Dataset Information

6 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Effect of Peritoneal Lavage With Clindamycin-Gentamicin Solution & Oncologic Outcome

ABSTRACT: Antibiotic lavage reduces bacterial contamination and decreases SSI infection rate. SSI leads to an immunocompromised situation, leaving unattended the neoplasm. It has been described that SSI may result in a worse oncologic outcome.

DISEASE(S): Colorectal Tumors,Colorectal Neoplasms

PROVIDER: 2186565 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Effect of peritoneal lavage in elective colorectal surgery: a randomised trial

Project description:Interventions: perform the paritoneal lavage with 3,000ml of warm saline not perform the peritoneal lavage Primary outcome(s): rate of SSI Study Design: Parallel Randomized

| 2620410 | ecrin-mdr-crc

bronchoalveolar lavage fluid

Project description:bronchoalveolar lavage fluid Metagenome

| PRJNA449183 | ENA

Effect of Peritoneal Lavage With Clindamycin-gentamicin Solution on Postoperative Colorectal Cancer Infection in Elective Surgery

Project description:Intrabdominal antibiotic irrigation will reduce wound and intrabdominal infection.

| 2108583 | ecrin-mdr-crc

Segmental Allergen Challenge Regulates Gene Expression In Bronchoalveolar Lavage (BAL) Cells From Atopic and Mild Asthmatic Subjects

2013-05-01 | GSE46159 | GEO

Segmental Allergen Challenge Regulates Gene Expression In Bronchoalveolar Lavage (BAL) Cells From Atopic and Mild Asthmatic Subjects

Project description:Segmental allergen challenge increases the percentage of eosinophils in bronchoalveolar lavage (BAL) cells. Mepolizumab, an anti-IL-5 therapeutic antibody, decreases the number of eosinophils in bronchoalveolar lavages (BAL). The use of both procedures allows to define genes that are either expressed by eosinophils or dependent on eosinophil presence in the airways. Cells from Bronchoalveolar lavages (BAL) are obtained by bronchoscopy before (V5) and 48 h after a segmental allergen challenge (V6) in atopic and mild astmatics. This procedure was repeated in the same two subjects 2 months later and 1 month after an injection of mepolizumab (V22 is before challenge and V23 after challenge). Cells were immediately lysed and isolated total RNAs were analyzed using the Human Genome 1.0 ST GeneChip arrays (Affymetrix, Santa Clara, CA).

2013-05-01 | E-GEOD-46159 | biostudies-arrayexpress

Clinical bronchoalveolar lavage (BAL) samples

Project description:Clinical bronchoalveolar lavage (BAL) samples Targeted loci

| PRJNA408304 | ENA

Cytological findings of intraluminal lavage after colorectal endoscopic submucosal dissection

Project description:Primary outcome(s): exfoliated tumor cells of intraluminal lavage before and after(beginning of lavage, after lavage of 500ml,1000ml,1500ml) colorectal endoscopic submucosal dissection

| 2626421 | ecrin-mdr-crc

Bronchoalveolar lavage of healthy human adults

Project description:Bronchoalveolar lavage of healthy human adults

| PRJNA637757 | ENA

Transcription profiling of bronchoalveolar lavage cells from AJ mice treated with urethane vs. controls

Project description:AJ mouse is susceptible to lung carcinogenesis from urethane treatment and is a good model for human adenocarcinoma. We completed a study using microarray analysis of bronchoalveolar lavage cells from control or urethane treated mice. A unique macrophage expression signature in the lung tumor microenvironment was able to correctly classify the lavage samples. Experiment Overall Design: RNA from bronchoalveolar lavage cells of age matched untreated AJ mice controls (C) or from urethane treated (T) AJ mice was prepared. Datasets were accurately classified using a unique macrophage gene expression signature derived from the tumor microenvironment.

2008-04-07 | E-GEOD-7258 | biostudies-arrayexpress

Bronchoalveolar lavage fluid reveals factors contributing to the efficacy of PD-1 blockade in lung cancer

Project description:Bronchoalveolar lavage is commonly performed to examine inflammation and responsible pathogens in lung diseases, and its findings may be used to assess the immune profile of the lung tumor microenvironment (TME). To investigate whether analyses of bronchoalveolar lavage fluid (BALF) can help identify non-small cell lung cancer (NSCLC) patients who respond to immune checkpoint inhibitors (ICIs), BALF and blood were prospectively collected before initiating nivolumab. The secreted molecules, microbiome, and cellular profiles based on BALF and blood analysis were compared regarding therapeutic effect in 12 patients. Compared to non-responders, responders showed significantly higher CXCL9 levels and greater diversity in the lung microbiome profile in BALF, and greater frequency of CD56+ subset in blood T cells, whereas no significant difference was found in PD-L1 expression of tumor cells. Antibiotic treatment in a preclinical lung cancer model significantly decreased CXCL9 in the lung TME, resulting in reduced sensitivity to nivolumab, which was reversed by CXCL9 induction in tumor cells. Thus, CXCL9 and the microbiome in the lung TME might be associated with each other, and their balance could contribute to nivolumab sensitivity in NSCLC patients. BALF analysis can help predict the efficacy of ICIs when performed along with currently approved examinations.

2022-04-07 | GSE193049 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data